Key statistics dashboard for Surrozen, Inc. (SRZN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Stock Data
| Price | $16.93 |
| Market Cap | $127M |
| Enterprise Value | $30.9M |
| Beta | 0.52 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.41 |
| Price / Book | -0.90 |
| P/S | 11.00 |
| EV/EBITDA | -0.09 |
| EV/Sales | 2.68 |
| EV/FCF | -0.88 |
| P/FCF | -3.62 |
| Earnings Yield | -168.21% |
| FCF Yield | -27.64% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 99.44% |
| EBIT Margin | -2885.33% |
| EBITDA Margin | -2883.84% |
| Operating Margin | -385.28% |
| Net Margin | -2885.33% |
| Return on Equity | 187.62% |
| Return on Assets | -287.29% |
| Return on Invested Capital | -40.84% |
| Return on Capital Employed | -41.61% |
Financial Health
| Current Ratio | 12.14 |
| Quick Ratio | 12.14 |
| Cash Ratio | 11.32 |
| Debt / Equity | -0.03 |
| Debt / Assets | 5.46% |
| Net Debt / EBITDA | 0.29 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.99 |
| Book Value per share | -18.75 |
| Cash per share | 8.75 |
| FCF per share | -3.00 |
| Tangible Book Value per share | -18.75 |
| Dividend per share | 0.00 |
Related companies: AGEN · ATOS · CGTX · GLSI · IMMX · IRD · SEER
Explore sector: Healthcare · Biotechnology
More sections of SRZN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks